Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it received the required controlled substances export approval from the DEA. The Company’s proprietary psilocybin drug (NM-1001), has been received at the…